IR News 2016

　Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa) today announces the completion of construction of a manufacturing building for APIs for clinical trials in the headquarters area (hereinafter the Building). Completion ceremony was held today.

　With completion of the Building, Nippon Shinyaku will be able to produce APIs for clinical trials such as highly active substances and nucleic acid medicine in-house. This improvement will lead to quick and flexible production of APIs which are necessary to develop new drugs as well as cost reduction.

　The Building equips 1,000-liter-large-scale synthesis machinery, containment facility and facility for isolation and purification. These facilities enable Nippon Shinyaku to respond to a wide range of API needs. In addition, the Building will contribute to improving our reliability of quality assurance because the Building is designed to meet the latest GMP standards and a number of regulatory criteria related to safety and environment protection.

　Making full use of the Building, we will further expedite our R&D activities.